Cargando…
Cost effectiveness of concurrent gemcitabine and cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in stages IIB–IVA cervical cancer
Autores principales: | Rajan, Narayan, Barraclough, Helen, Puri, Tarun, Orlando, Mauro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4434144/ https://www.ncbi.nlm.nih.gov/pubmed/26076001 http://dx.doi.org/10.1016/j.gore.2014.09.002 |
Ejemplares similares
-
Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer
por: Kong, Tae Wook, et al.
Publicado: (2012) -
Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin
por: Lachkar, Bouchra, et al.
Publicado: (2018) -
Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Patients With Stage IIB-IVA Cervical Cancer: A Randomized Phase III Trial
por: He, Shasha, et al.
Publicado: (2022) -
Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
por: Sugimoto, Kazuma, et al.
Publicado: (2022) -
Cisplatin/gemcitabine: Pancytopenia: case report
Publicado: (2021)